Literature DB >> 15292068

Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice.

Lucia Centurione1, Angela Di Baldassarre, Maria Zingariello, Domenico Bosco, Valentina Gatta, Rosa Alba Rana, Vincenzo Langella, Antonio Di Virgilio, Alessandro M Vannucchi, Anna Rita Migliaccio.   

Abstract

Deletion of megakaryocytic-specific regulatory sequences of GATA-1 (Gata1(tm2Sho) or GATA-1(low) mutation) results in severe thrombocytopenia, because of defective thrombocytopoiesis, and myelofibrosis. As documented here, the GATA-1(low) mutation blocks megakaryocytic maturation between stage I and II, resulting in accumulation of defective megakaryocytes (MKs) in the tissues of GATA-1(low) mice. The block in maturation includes failure to properly organize alpha granules because von Willebrand factor is barely detectable in mutant MKs, and P-selectin, although normally expressed, is found frequently associated with the demarcation membrane system (DMS) instead of within granules. Conversely, both von Willebrand factor and P-selectin are barely detectable in GATA-1(low) platelets. Mutant MKs are surrounded by numerous myeloperoxidase-positive neutrophils, some of which appear in the process to establish contact with MKs by fusing their membrane with those of the DMS. As a result, 16% (in spleen) to 34% (in marrow) of GATA-1(low) MKs contain 1 to 3 neutrophils embedded in a vacuolated cytoplasm. The neutrophil-embedded GATA-1(low) MKs have morphologic features (high electron density and negativity to TUNEL staining) compatible with those of cells dying from para-apoptosis. We suggest that such an increased and pathologic neutrophil emperipolesis may represent one of the mechanisms leading to myelofibrosis by releasing fibrogenic MK cytokines and neutrophil proteases in the microenvironment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292068     DOI: 10.1182/blood-2004-01-0193

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.

Authors:  Marco Pizzi; Richard T Silver; Ariella Barel; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-08-14       Impact factor: 7.842

Review 2.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

3.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

4.  Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Massimo Sanchez; Mauro Valeri; Giovanni Migliaccio; Alessandro Maria Vannucchi; Maria Zingariello; Angela Di Baldassarre; Barbara Ghinassi; Rosa Alba Rana; Yvette van Hensbergen; Willem E Fibbe
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

5.  Bone marrow findings at diagnosis in patients with multisystem langerhans cell histiocytosis.

Authors:  Maria Laura Galluzzo; Jorge Braier; Sergio D Rosenzweig; Maria T Garcia de Dávila; Diego Rosso
Journal:  Pediatr Dev Pathol       Date:  2010 Mar-Apr

6.  New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.

Authors:  Michal Bar-Natan; Ronald Hoffman
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

Review 7.  Megakaryocytes as immune cells.

Authors:  Pierre Cunin; Peter A Nigrovic
Journal:  J Leukoc Biol       Date:  2019-01-15       Impact factor: 4.962

8.  The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.

Authors:  Lisa Pieri; Costanza Bogani; Paola Guglielmelli; Maria Zingariello; Rosa Alba Rana; Niccolò Bartalucci; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

9.  Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Alessandro Maria Vannucchi; Hongyu Ni; Mingjiang Xu; Yi Jiang; Betty Nakamoto; Thalia Papayannopoulou; Ronald Hoffman
Journal:  Exp Hematol       Date:  2008-02       Impact factor: 3.084

10.  Cross-talk of GATA-1 and P-TEFb in megakaryocyte differentiation.

Authors:  Kamaleldin E Elagib; Ivailo S Mihaylov; Lorrie L Delehanty; Grant C Bullock; Kevin D Ouma; Jill F Caronia; Sara L Gonias; Adam N Goldfarb
Journal:  Blood       Date:  2008-09-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.